Medtech companies hit the brakes on large mergers and acquisitions last year with 11 transactions valued above $1 billion compared with 21 “megadeals” in 2021, according to data from consulting and accounting firm EY. The slowdown may be short-lived, industry observers say. While medtech dealmakers and advisers expect a slow start to 2023, they point out that despite higher interest rates and a volatile stock market, there are signs that buying and selling medtech companies in whole or in part is is poised to rebound.
Read the full article: Medtech M&A Outlook for 2023 //
Source: https://www.medtechdive.com/news/medtech-mergers-acquisitions-outlook-2023/641615